<DOC>
	<DOC>NCT01851512</DOC>
	<brief_summary>This is a single-blind, randomized, comparative, phase I study to evaluate the tolerability, safety and pharmacokinetic characteristics of human chorionic gonadotropin between two recombinant hCG products named DA-3803 injection and ovidrel liquid injection, in healthy subjects. The subjects will injected with these two injections at the the 21day-interval of time and their conditions including vital signs, blood, clinical examination will be carefully observed.</brief_summary>
	<brief_title>A Study to Evaluate the Tolerability, Safety and Pharmacokinetic Characteristics of DA-3803</brief_title>
	<detailed_description />
	<mesh_term>Infertility</mesh_term>
	<mesh_term>Chorionic Gonadotropin</mesh_term>
	<criteria>No medical history relating to the alimentary system, liver system, heart system, haematological disease Ideal body weight +/ 20% acute disease within 28 days medical history that might affect the absorption, distribution, secretion, metabolism of drugs metrectomy surgery desexualization tubal ligation menopause pregnancy not able to use contraception drink alcohol more than 14 units/week smoker who smokes 10 or more cigarettes</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>May 2013</verification_date>
</DOC>